1. Авдеев С.В. Применение тиотропия бромида при бронхиальной астме. Справ. поликлин. врача. 2008; 10: 24–8.
2. Синопальников А.И. Тиотропия бромид – новый антихолинергический препарат длительного действия. РМЖ. 2003; 11 (22): 1256–61.
3. Фисенко В.П. Тиотропия бромид (спирива) – новый М-холиноблокатор для лечения хронических обструктивных болезней легких. Пульмонология. 2003; 4: 100–4.
4. Чучалин А.Г. Тяжелая бронхиальная астма. РМЖ 2000; 8 (12): 482–6.
5. Цой А.Н. Спирива: новое средство терапии хронической обструктивной болезни легких. Cons. Med. 2003; 5 (10): 3–6.
6. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs 2001; 10: 733–40.
7. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000; 117 (2 Suppl.): 63–8.
8. Disse B, Reichi R, Speck G et al. A novel long-acting anticholinergic bronchodilator. Life Sci 1993; 52: 537–44.
9. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–40.
10. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–24.
11. Vincken W, van Noord JA, Greethorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiptropium. Eur Respir J 2002; 19: 209–16.
12. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967–75.
13. Hansel TT, Barnes PJ. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Tod 2002; 38: 585–600.
14. Leusch A, Eichhorn B, Muller G et al. Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. Biopharm Drug Dispos 2001; 22: 199–212.
15. van Noord JA, Smeets JJ, Custers FL et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 639–44.
16. Donohue JF, van Noord JA, Babeman ED et al. A 6-month, placebo-controlled comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
17. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441–9.
18. Magnussen H, Bugnas B, van Noord J еt al. Respir Med J 2008; 102: 50–6.
19. Fabbri LM, Romagnoli M, Corbetta L et al., Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease, Am J Respir Crit Care Med 2003; 167: 418–24.
20. Lanes SF, Garrett JE, Wentworth CE et al., The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials. Chest 1998; 114: 365–72.
21. Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effect of ipratropium bromide in adults with acute asthma. Am J Med 1999; 107: 363–70.
22. Israel E, Chinchilli VM, Ford J et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505–12.
23. Celli BR, MacNee. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932–46.
24. Vermeire PA, Pride NB. A «Splitting» look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. Eur Respir J 1991; 4: 490–6.
25. Wenzel SE, Schwartz LB, Langmack LE et al., Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001–8.
26. Saetta M, Di Stefano A, Maestrelli P et al., Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646–52.
27. Kesten S, Rebuck AS. Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest 1994; 105: 1042–5.
28. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53: 129–36.
29. Magnussen H, Richter K, Taube C. Are chronic obstructive pulmonary disease (COPD) and asthma different diseases. Clin Exp Allergy 1998; 28 (Suppl. 5): 187–94.
30. Tashkin D, Kesten S. Long term treatment benefits with tiotropium in COPD patients with and without acute bronchodilator responses. Chest 2003; 123: 1441–9.
31. Tashkin DP, Celli B, Senn S et al. for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
32. Decramer M, Celli B, Tashkin DP et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004; 1: 303–12.
33. Tashkin DP, Celli B, Decramer M et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31: 742–50.

Н.П.Княжеская